Cytek Biosciences, Inc.
NASDAQ:CTKBMedical - Devices
-$0.11 today
- Market cap
- $774.24M
- Beta
- 1.19
- P/E (TTM)
- -6.7
- EPS (TTM)
- -$0.57
Volume 1.05M
Average 0.88M
CTKB Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Cytek Biosciences, Inc.NASDAQ: CTKB
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 31.1% from a year ago
Cash & equivalents stood at $65.67M at the end of Q1 FY2026, down 31.1% from a year earlier and down 27.7% from the prior quarter. Over 3 fiscal years it compounded at -32.6% a year.
Context
- Cash & equivalents amounted to 14.6% of total assets at the end of Q1 FY2026, down 5.1 pp from a year earlier.
- Cash & equivalents increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -31.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 90.85M USD
- Year-over-year change
- -8.0%
- 4-year CAGR
- -29.3%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 90.85M | -8.0% |
| FY2024 | 2024-12-31 | 98.72M | -41.0% |
| FY2023 | 2023-12-31 | 167.3M | -43.6% |
| FY2022 | 2022-12-31 | 296.6M | -18.7% |
| FY2021 | 2021-12-31 | 364.62M | — |
Cash & Equivalents vs competitors
How CTKB compares with its peers on the latest reported figures
- CTKB's Mar 2026 cash & equivalents of $65.67M is the lowest of the 6 companies compared; the peer median is $517M.
- Its year-over-year change of -31.1% is the lowest of 6, against a peer median of +40.0%.
- Cash & equivalents amounts to 14.6% of total assets for CTKB, versus a peer median of 12.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jul 2026 | $1.76B | +14.5% | +19.3% | 12.6% | |
| Sep 2026 | $526.19M | +21.7% | +29.2% | 49.5% | |
| Jun 2026 | $517M | +40.0% | +7.0% | 5.0% | |
| Mar 2026 | $265.77M | +76.1% | +13.3% | 41.6% | |
| Jun 2026 | $184.9M | +101.0% | -22.6% | 3.1% | |
| Mar 2026 | $65.67M | -31.1% | -32.6% | 14.6% | |
| Peer median (excluding CTKB) | $517M | +40.0% | +13.3% | 12.6% | |
Competitors are the stored peer set for CTKB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 364.62M | 296.6M | 167.3M | 98.72M | 90.85M |
| Short-term Investments | 0 | 44.55M | 95.11M | 179.15M | 170.68M |
| Net Receivables | 29.63M | 50.88M | 56.12M | 60.59M | 72.13M |
| Inventory | 32.17M | 48.15M | 60.88M | 43.89M | 48.43M |
| Other Current Assets | 708K | 6.7M | 2.56M | 1.97M | 2.98M |
| Total Current Assets | 431.73M | 454.02M | 392.06M | 396.45M | 392M |
| Property, Plant & Equipment (Net) | 5.85M | 27.57M | 29.26M | 28.13M | 29.32M |
| Goodwill | 10.14M | 10.14M | 16.18M | 16.66M | 16.7M |
| Intangible Assets | 4.74M | 4.33M | 23.08M | 20.13M | 16.82M |
| Long-term Investments | 0 | 0 | 1.6M | 1.6M | 0 |
| Tax Assets | 9.17M | 20.46M | 30.49M | 33.37M | 0 |
| Other Non-current Assets | 1.67M | 2.96M | 1.79M | 3.16M | 6.7M |
| Total Non-current Assets | 31.57M | 65.46M | 102.4M | 103.05M | 69.55M |
| Total Assets | 463.31M | 519.48M | 494.46M | 499.5M | 461.54M |
| Account Payables | 3.03M | 4.81M | 3.03M | 5.53M | 6.41M |
| Short-term Debt | 0 | 580K | 565K | 4.66M | 6.3M |
| Tax Payables | 3.88M | 1.67M | 1.3M | 3.56M | 0 |
| Deferred Revenue | 8.1M | 14.54M | 24.13M | 26.61M | 29.57M |
| Other Current Liabilities | 12.04M | 17.3M | 16.71M | 1.86M | 18.14M |
| Total Current Liabilities | 33.18M | 49.04M | 56.23M | 67.66M | 77.8M |
| Long-term Debt | 0 | 2.27M | 1.65M | 1.05M | 525K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 9.79M | 13.12M | 15.13M | 16.1M | 18.34M |
| Other Non-current Liabilities | 14.95M | 17.18M | 18.91M | 11.4M | 9.09M |
| Total Non-current Liabilities | 24.74M | 44.89M | 45.17M | 36.1M | 42M |
| Total Liabilities | 57.92M | 93.93M | 101.39M | 103.76M | 119.8M |
| Common Stock | 126K | 135K | 131K | 129K | 129K |
| Retained Earnings | (19.61M) | (17.03M) | (29.18M) | (35.2M) | (101.74M) |
| Accumulated OCI | 897K | (697K) | (1.28M) | 16K | 2.24M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 343K | 251K | 0 | 0 | 0 |
| Total Equity | 405.39M | 425.55M | 393.06M | 395.74M | 341.74M |
| Total Debt | 0 | 18.09M | 14.14M | 17.02M | 23.74M |
| Net Debt | (364.62M) | (278.51M) | (153.16M) | (81.7M) | (67.11M) |
Cytek Biosciences, Inc.
NASDAQ:CTKB
Intrinsic Alpha fair value
Locked
Current Price
$5.92
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.